scholarly journals The role of ultrasonographic findings to predict molecular subtype, histologic grade, and hormone receptor status of breast cancer

2015 ◽  
Vol 21 (6) ◽  
pp. 448-453 ◽  
Author(s):  
Filiz Celebi ◽  
Kezban Nur Pilanci ◽  
Cetin Ordu ◽  
Filiz Agacayak ◽  
Gul Alco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Molecular Subtype ◽  
Hormone Receptor Status ◽  
Histologic Grade ◽  
Receptor Status

Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status

2009 ◽  
Vol 21 (3) ◽  
pp. 399-409 ◽  
Author(s):  
Joan E. Cunningham ◽  
Alberto J. Montero ◽  
Elizabeth Garrett-Mayer ◽  
Hans J. Berkel ◽  
Bert Ely
Keyword(s):  
Breast Cancer ◽  
Racial Differences ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Histologic Grade ◽  
Breast Cancer Subtypes ◽  
Receptor Status ◽  
Cancer Subtypes

Hormone receptor status in primary breast cancer—time for a consensus?

2002 ◽  
Vol 38 (9) ◽  
pp. 1201-1203 ◽  
Author(s):  
G.C Wishart ◽  
M Gaston ◽  
A.A Poultsidis ◽  
A.D Purushotham
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Receptor Status

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

2021 ◽  
pp. 41-44
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Histological Grade ◽  
Systemic Disease ◽  
Lymph Node Involvement ◽  
Hormone Receptor Status ◽  
Major Health Problem ◽  
Receptor Status ◽  
Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

scholarly journals Is the biology of breast cancer changing? A study of hormone receptor status 1984–86 and 1996–1997

2008 ◽  
Vol 34 (10) ◽  
pp. 1172
Author(s):  
Sylvia Brown ◽  
E. Mallon ◽  
J. Edwards ◽  
F. Campbell ◽  
L. McGlynn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status

scholarly journals Effect of intraoperative radiotherapy on wound healing in breast cancer patient post breast conserving surgery, KSUMC, Riyadh, Saudi Arabia: Case series and review of literature.

2019 ◽  
Vol 6 (06) ◽  
pp. 4505-4510
Author(s):  
Dr. Maha Alamodi Alghamdi ◽  
Abdulaziz Saleh Altwjri ◽  
Abdullah Alsuhaibani ◽  
Abdulaziz Alsaif
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
External Beam Radiotherapy ◽  
Intraoperative Radiotherapy ◽  
Breast Conserving Surgery ◽  
Hormone Receptor Status ◽  
Wound Complications ◽  
External Beam ◽  
X Rays ◽  
Receptor Status

Intraoperative radiotherapy during breast-conserving surgery is being studied as an alternative to 6 weeks of external beam radiotherapy (EBRT) for low-risk women; it can be delivered using electrons (intraoperative electron radiotherapy, IOERT) or 50-kV X-rays. Intraoperative radiation therapy (IORT) may pose a risk for wound complications.  Between March 2018 and June 2018, 5 breast cancer patients, all eligible for breast conserving surgery (BCS), were treated at the King Saud Medical city with IORT using the IOERT. Complete data sets for age, stage (T, N, and M), and histology and hormone receptor status were available in 5 cases. Parameters to identify eligible patients are as follows: ESTRO: >50 years, invasive ductal carcinoma/other favourable histology (IDC), T1-2 (≤3 cm), N0, any hormone receptor status, M0; ASTRO: ≥60 years, IDC, T1, N0, positive estrogen hormone receptor status, M0; TARGIT E “elderly”, risk adapted radiotherapy with IORT followed by external beam radiotherapy in case of risk factors in final histopathology. Consecutive patients operated on with the same surgical technique and given IORT were included. Wound complications were evaluated.

scholarly journals Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition

2012 ◽  
Vol 132 (7) ◽  
pp. 1667-1678 ◽  
Author(s):  
Karen Steindorf ◽  
Rebecca Ritte ◽  
Piia-Piret Eomois ◽  
Annekatrin Lukanova ◽  
Anne Tjonneland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Prospective Investigation

Assessment of hormone receptor status in breast cancer

2007 ◽  
Vol 57 (12) ◽  
pp. 784-790 ◽  
Author(s):  
Rie Horii ◽  
Futoshi Akiyama ◽  
Yoshinori Ito ◽  
Takuji Iwase
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Receptor Status

Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998

2003 ◽  
Vol 21 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Christopher I. Li ◽  
Janet R. Daling ◽  
Kathleen E. Malone
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Receptor ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Incidence Rates

Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis. Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds. Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.

Sign in / Sign up

Export Citation Format

Share Document